Covidien reports positive data from ClosureFast trial

Covidien has announced positive data from a study assessing the benefits offered by its ClosureFast radiofrequency ablation system.

The ClosureFast Long-Term European Multi-Center Study took place over a five-year period and evaluated the performance of this minimally invasive endovascular therapy for treatment of chronic venous insufficiency (CVI).

Conducted at eight centres across Europe, the trial demonstrated sustained treatment success in anatomical and clinical categories, thus supporting the leading position of the device in endovenous vein treatment.

CVI  occurs when valves in the veins of the lower leg no longer function to push blood back to the heart and can result in lifestyle-limiting lower leg pain, skin damage and ulcerations if left untreated.

Dr Mark Turco, chief medical officer for vascular therapies at Covidien, said: "This pivotal study provides substantial long-term data on relevant endpoints to help clinicians decide the appropriate treatment for their patients, thus defining Covidien’s commitment to a strong foundation of clinical research."